Company Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 11/07/2025 BST			5-day change	1st Jan Change
8.890 ^USD	-1.33%		+1.02%	-60.97%

07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
07-08	Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	CI

Business description: Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Number of employees: 4

Sales by Activity: Quoin Pharmaceuticals, Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024

See all business segments

Executive Committee: Quoin Pharmaceuticals, Ltd.

Manager	Title	Age	Since
Denise Carter COO	Chief Operating Officer	56	27/10/2021
Michael Myers CEO	Chief Executive Officer	63	27/10/2021
Gordon Dunn DFI	Director of Finance/CFO	61	31/10/2021

See QUOIN PHARMACEUTICALS, LTD. governance

Composition of the Board of Directors: Quoin Pharmaceuticals, Ltd.

Director	Title	Age	Since
Michael Myers CHM	Chairman	63	27/10/2021
Denise Carter BRD	Director/Board Member	56	27/10/2021
Dennis Langer BRD	Director/Board Member	74	27/10/2021
Natalie Leong BRD	Director/Board Member	40	27/10/2021
Anthony Culverwell BRD	Director/Board Member	69	27/10/2021
Michael Sember BRD	Director/Board Member	-	27/10/2021
Joseph Cooper BRD	Director/Board Member	67	27/10/2021

Composition of the Board of Directors

Shareholders: Quoin Pharmaceuticals, Ltd.

Name	Equities	%	Valuation
UBS Securities LLC 559.87 %	6,265	559.87 %	57 826 $
Apollon Wealth Management LLC 204.29 %	2,286	204.29 %	21 100 $
RhumbLine Advisers LP 106.61 %	1,193	106.61 %	11 011 $
Raymond James Financial Services Advisors, Inc. 64.16 %	718	64.16 %	6 627 $
Lido Advisors LLC (13F Subfiler) 60.05 %	672	60.05 %	6 203 $

Name	Equities	%	Valuation
Michael Myers 16.35 %	602,808	16.35 %	6 M $
Denise Carter 16.35 %	602,648	16.35 %	6 M $
Gordon Dunn 4.099 %	151,077	4.099 %	1 M $
Anthony Culverwell 2.722 %	100,317	2.722 %	925 926 $
Dennis Langer 0.001438 %	53	0.001438 %	489 $

List of QUOIN PHARMACEUTICALS, LTD. shareholders

Company details: Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd.

42127 Pleasant Forest Court

20148-7349, Ashburn

http://www.quoinpharma.com

address Quoin Pharmaceuticals, Ltd.(QNRX)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUOIN PHARMACEUTICALS, LTD.	-1.33%	+1.02%	-61.28%	-99.65%	5.23M
LONZA GROUP AG	-0.95%	+0.68%	+8.88%	+1.62%	50.02B
BEONE MEDICINES LTD.	-1.22%	+1.96%	+64.49%	+40.10%	29.65B
CELLTRION, INC.	0.00%	+0.34%	+3.30%	+8.18%	28.69B
IQVIA HOLDINGS INC.	-1.65%	-0.88%	-27.38%	-23.76%	28.16B
EUROFINS SCIENTIFIC SE	-0.03%	-0.39%	+23.62%	-20.18%	12.7B
ICON PUBLIC LIMITED COMPANY	-1.02%	+0.28%	-55.21%	-27.95%	11.96B
ASCENDIS PHARMA A/S	-0.87%	+0.45%	+26.71%	+94.27%	10.59B
QIAGEN N.V.	-0.87%	-0.43%	+10.94%	-2.87%	10.42B
TEMPUS AI, INC.	-4.56%	-6.71%	+43.06%	-	9.85B
Average	-1.25%	+0.33%	+3.71%	-3.36%	19.21B
Weighted average by Cap.	-1.07%	+0.62%	+11.14%	+6.66%